JOINT FILING AGREEMENT
Exhibit 1.04
The undersigned hereby agree that they are filing this statement on Schedule 13D jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D with respect to the Common Stock, par value $0.0001 per share, of Epizyme, Inc., a Delaware corporation, beneficially owned by each of them. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13D.
IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 7th day of July, 2022.
| XXXXX X.X. | ||
| /s/ Xxxxx Xxxx | ||
| By: | Xxxxx Xxxx | |
| Its: | Chief Executive Officer | |
| XXXXX PHARMA SAS | ||
| /s/ Xxxxx Xxxx | ||
| By: | Xxxxx Xxxx | |
| Its: | President | |
| XXXXX BIOPHARMACEUTICALS, INC. | ||
| /s/ Xxxxxxx Xxxxxxxx | ||
| By: | Xxxxxxx Xxxxxxxx | |
| Its: | Executive Vice President and President, | |
| North America | ||
| HIBERNIA MERGER SUB, INC. | ||
| /s/ Xxxxxxxxxx Xxxxxx | ||
| By: | Xxxxxxxxxx Xxxxxx | |
| Its: | Chief Executive Officer and President | |
